

**ROLE OF TUMOR NECROSIS FACTOR -LIKE WEAK
INDUCER OF APOPTOSIS /FIBROBLAST GROWTH
FACTOR INDUCIBLE MOLECULE 14 PATHWAY IN
LUPUS NEPHRITIS**

Thesis

*Submitted in partial fulfillment of M.D. Degree in Physical Medicine,
Rheumatology and Rehabilitation*

By

Miriam Raafat Sadek Bekhit

*M.B., B.Ch. &M. Sc. Physical Medicine, Rheumatology and Rehabilitation |
Faculty of Medicine- Ain Shams University*

Under supervision of

Prof. Dr. Nadia Salah Kamel Abd ELBar

*Professor of Physical Medicine, Rheumatology and Rehabilitation
Faculty of Medicine, Ain Shams University*

Prof. Dr. Manal Osman Mohammed

*Professor of Physical Medicine, Rheumatology and Rehabilitation
Faculty of Medicine, Ain Shams University*

Dr. Nouran Mostafa Abaza

*Assistant Professor of Physical Medicine
Rheumatology and Rehabilitation*

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

2018

**دور مثيل عامل النخر الورمى المحفز لموت الخلايا المبرمج/عامل
النمو الليفى المستحث ١٤ فى الإلتهاب الكلوى فى مرضى
□ الذئبة الحمراء**

رسالة

توطئة للحصول علي درجة الدكتوراة في الطب الطبيعي و الروماتيزم و التأهيل
مقدمة من

ميريام رافت صادق بخيت/الطبيبة

ماجستير الطب الطبيعي والروماتيزم و التأهيل
كلية الطب جامعة عين شمس
تحت إشراف

□ أ.د/ نادية صلاح كامل عبد البر

أستاذ الطب الطبيعي والروماتيزم و التأهيل
كلية الطب- جامعة عين شمس

أ.د/ منال عثمان محمد

أستاذ الطب الطبيعي والروماتيزم و التأهيل
كلية الطب- جامعة عين شمس

□ د/ نوران مصطفى أباطه

أستاذ مساعد الطب الطبيعي والروماتيزم و التأهيل
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس



Acknowledgement

*First and foremost praises and thanks to **God** for His showers of blessings throughout my thesis to complete the work successfully.*

*I owe my most sincere gratitude to **Prof. Dr. Nadia Salah Kamel**, Head of Physical Medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, Ain Shams University. Her expertise, invaluable guidance, constant encouragement, affectionate attitude, understanding, patience and healthy criticism have been very helpful to complete this thesis.*

*I am immensely indebted to **Prof. Dr. Manal Osman Mohammed**, Professor of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University. Her vision, sincerity and motivation have deeply inspired me. It was a great privilege and honor to work under her guidance.*

*I would like to express my deepest appreciation to **Assist Prof. Dr. Nouran Mostafa Abaza**, Assistant Professor of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, for her kind assistance, valuable suggestions and providing coherent answers to my questions.*

*I take this opportunity to express my deep sense of gratitude and respectful regards to **Dr. Somia Ahmed Saad** Lecturer of Pathology, Faculty of Medicine, Ain Shams University for her help with the pathology work carried throughout the research and presenting the slides as clearly as possible.*

CONTENTS

Subjects	Page
• List of Abbreviations	I
• List of table	IV
• List of Figures	VI
• Introduction	1
• Aim of the Work.....	3
• Review of literature:	
Chapter 1: Pathogenesis of Lupus Nephritis.....	4
Chapter 2: Pathology of Lupus Nephritis.....	29
Chapter 3: TWEAK/Fn 14	34
Chapter 4: TWEAK/Fn 14 in Lupus Nephritis	52
• Patients And Methods.....	61
• Results.....	73
• Discussion.....	122
• Summary and Conclusion.....	144
• Recommendations	148
• References	149
• Appendices	173
• Arabic Summary	

LIST OF ABBREVIATIONS

Abs	Antibodies
aCL	Anti Cardiolipin
AIDS	Acquired immune deficiency syndrome
ANA	Anti nuclear antibody
Anti-Sm	Anti Smith antibody
APRIL	Antigen presenting cells
BAFF	B cell activating factor
BBB	Blood–brain barrier
BLyS	B Lymphocyte Stimulator
C	Complement
CCL	c-c motif ligand
CCR	c-c chemokine receptor
CD	Cluster of differentiation
cGVHD	chronic graft-versus-host disease
cIAP1/2	cellular inhibitor of apoptosis-1/2
CXCR	C-X-C chemokine receptor
DC	Dendritic cell
DNA	Deoxyribonucleic acid
DNP	Deoxyribonucleoproteins
DR	Death receptor
dsDNA	Double stranded deoxyribonucleic acid

List of Abbreviations

ECM	Extracellular matrix
EMT	Epithelial-to-mesenchymal transdifferentiation
FGF	Fibroblast growth factor
Fn 14	Fibroblast growth factor-inducible molecule 14
FSGS	Focal segmental glomerulosclerosis
GBM	Glomerular basement membrane
GFR	Glomerular filtration rate
HIN200	Helicase, pyrin and hematopoietic expression interferon inducible nature 200
IAP	inhibitor of apoptosis
IC	Immune Complex
ICAM-	Intercellular adhesion molecule 1
IFN	Interferon
IFNAR	Interferon alpha receptor
Ig	Immunoglobulin
IKK	Inhibitor of kappaB kinase
IL	Interleukin
iNOS	Inducible nitric oxide synthase
IP-10	Interferon gamma -induced protein 10
IRF	Interferon regulatory factor
ISN/RPS	International Society of Nephrology and Renal Pathology Society

List of Abbreviations

Jak-Tyk2	Janus Kinase1- Tyrosine Kinase 2
KO	Knockout
LA	Lupus anticoagulant
LN	Lupus nephritis
mAb	Monoclonal antibodies
MACO	Middle cerebral artery occlusion
MAPK	Mitogen-activated protein kinases
MCP	Monocyte Chemotactic protein
MDA-5	Melanoma differentiation-associated gene 5
MHC	Major Histocompatibility Complex
MIP	Macrophage inflammatory protein
MMPs	Matrix metalloproteinases
MRL/lpr	Murphy Roths Large lymphoproliferative strain
MyD88	Myeloid differentiation factor 88
NETs	Neutrophil extracellular traps
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NIK	NF-κB-inducing kinase
NK	Natural killer
NO	Nitric oxide
NTN	Nephrotoxic serum transfer nephritis
PBMC	Peripheral blood mononuclear cell

List of Abbreviations

pDC	Plasmacytoid dendritic cell
PDGF	Platelet derived growth factor
PKC	Protein kinase C
RANTES	Regulated on activation, normal T cell expressed and secreted
RIG-I	Retinoic acid inducible gene I
RING	Really interesting new gene
RIP1	Receptor-interacting protein 1
RLR	Retinoic acid inducible gene I like receptor
RNA	Ribonucleic acid
ROS	Reactive oxygen species
SIGIRR	Single Ig IL-1 related receptor
SLE	Systemic lupus erythematosus
SLEADI	SLE disease activity index
SLICC	Systemic Lupus International Collaborating Clinics criteria
SMCs	smooth muscle cells
snRNP	Small nuclear ribonucleoprotein
STAT	Signal transducer and activator of transcription
STING	Stimulator of interferon gene
STING	Stimulator of interferon gene
TACI	Transmembrane activator and calcium modulating ligand interactor
TGF-β	Transforming growth factor β

List of Abbreviations

Th	T helper
THD	TNF homology domain
TIMPs	Tissue inhibitor of metalloproteinases
TIR 8	Toll interleukin 1 receptor 8
TLR	Toll like receptor
TNF	Tumor necrosis factor
TNFRSF 12	Tumor necrosis factor receptor superfamily member 12
TNFSF 12	Tumor necrosis factor ligand superfamily member 12
TRAF	TNF receptor associated factor
TReg	T regulatory
TREX1	Three prime repair exonuclease 1
TRIF	Toll-receptor associated activator of interferon
TWEAK	Tumor necrosis factor-like weak inducer of apoptosis
uTWEAK	Urinary Tumor necrosis factor-like weak inducer of apoptosis
VCAM-1	Vascular cell adhesion molecule 1
VEGF	Vascular endothelial growth factor
WHO	World Health Organization
ZO-1	Zonula occludens-1

LIST OF TABLE

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
Table (1)	Autoantibodies with pathogenic potential in patients with LN	14
Table (2)	Binding of anti-dsDNA antibodies to resident renal cells and the effect on cellular function	18
Table (3)	The 1995 WHO classification for LN	31
Table (4)	International Society of Nephrology/ Renal Pathology Society (ISN/ RPS) classification of nephritis	32
Table (5)	National Institutes of Health version of activity and chronicity indices	33
Table (6)	Comparison between the studied groups as regards the demographic characteristics	74
Table (7)	Comparison between groups I and II as regards clinical data	75
Table (8)	Comparison between groups I and II as regards SLEDAI score	76
Table (9)	Distribution of SLE patients group according to total SLEDAI score	77
Table (10)	Distribution of SLE patients group according to extra renal SLEDAI score	77
Table (11)	Comparison between groups I and II as regards laboratory parameters	79
Table (12)	Comparison between serum TWEAK levels among studied groups	80
Table (13)	Comparison between urinary TWEAK levels among studied groups	0
Table (14)	Pairwise comparison between serum TWEAK levels among studied groups	81
Table (15)	Pairwise comparison between urinary TWEAK levels among studied groups	82
Table (16)	Comparison between groups I and II as regards immunologic profile	83
Table (17)	Comparison of serum TWEAK levels among SLE patients group with different clinical parameters	85
Table (18)	Comparison of serum TWEAK levels among SLE patients group with different laboratory	86

List of Table

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
	data	
Table (19)	Comparison of urinary TWEAK levels among SLE patients group with different clinical parameters	88
Table (20)	Comparison of urinary TWEAK levels among SLE patients group with different laboratory data	89
Table (21)	Comparison between serum and urinary TWEAK levels and extra renal SLEADI score in groups I and II	90
Table (22)	Comparison between mean levels of Fn 14 Allred score, sTWEAK, uTWEAK and renal pathological grading	91
Table (23)	Correlation between serum TWEAK and different studied parameters	114
Table (24)	Correlation between urinary TWEAK and different studied parameters	115
Table (25)	Correlation between Fn 14 Allred score and different studied parameters	118
Table (26)	Diagnostic performance of serum and urinary TWEAK	119
Table (27)	Diagnostic characteristics of serum TWEAK	120
Table (28)	Diagnostic characteristics of urinary TWEAK	121

LIST OF FIGURES

<i>Fig. No.</i>	<i>Subject</i>	<i>Page</i>
Fig. (1)	Innate signaling pathways leading to type I interferon production	6
Fig. (2)	Stimulation of type I interferon by cell debris and immune complexes	10
Fig. (3)	Domain architecture of TWEAK (A) and Fn14 (B)	36
Fig. (4)	Model for the role of TWEAK/Fn14 pathway in health and disease	38
Fig. (5)	Mechanisms of TWEAK/Fn14-induced apoptosis	41
Fig. (6)	Intracellular pathways activated by TWEAK	43
Fig. (7)	Overview of TWEAK/Fn14 activation in the pathogenesis of renal fibrosis	58
Fig. (8)	Comparison between patients and controls regarding serum TWEAK	81
Fig. (9)	Comparison between patients and controls regarding urinary TWEAK	82
Fig. (10)	The frequencies of ISN/RPS classification among LN patients	92
Fig. (11)	Mesangial proliferative GN ISN/RPS class II LN showing mesangial hypercellularity, H&E \times 400	93
Fig. (12)	A specimen from mesangial proliferative GN ISN/RPS class II LN patient showing moderate tubular atrophy with hyaline casts (thyroidization) (arrow) and interstitial fibrosis, H&E \times 200..	93
Fig. (13)	Same specimen as above showing the interstitial fibrosis by MT (green color) \times 200	94
Fig. (14)	A specimen from mesangial proliferative GN ISN/RPS class II LN patient showing periglomerular fibrosis, MT \times 200	94
Fig. (15)	Diffuse proliferative GN ISN/RPS class IV (A/C) showing increased cellularity and wire loop thickening of the capillary walls (arrow), H&E \times 200	95
Fig. (16)	A specimen from diffuse proliferative GN ISN/RPS class IV LN patient showing dense interstitial inflammation, H&E \times 200	95
Fig. (17)	A specimen from diffuse proliferative GN ISN/RPS class IV-G (A/C) LN patient showing	96

List of Figures

Fig. No.	Subject	Page
	global glomerular sclerosis, MT \times 400	
Fig. (18)	A specimen from diffuse proliferative GN ISN/RPS class IV-G (A/C) LN patient showing mild tubular atrophy (blue arrows), moderate interstitial inflammation and segmental glomerulosclerosis (black arrow), H&E \times 200	96
Fig. (19)	Same specimen as above showing segmental glomerulosclerosis, MT \times 200	97
Fig. (20)	A glomerulus from diffuse proliferative GN ISN/RPS class IV LN showing segmental fibrinoid necrosis (circle), H&E \times 400	97
Fig. (21)	A glomerulus from diffuse proliferative GN ISN/RPS class IV-G (A/C) LN patient showing dense glomerular neutrophilic infiltration along with loop thickening of capillary walls, H&E \times 400.	98
Fig. (22)	A glomerulus from same specimen but another field showing cellular crescent (arrow), H&E \times 400	98
Fig. (23)	A specimen from diffuse proliferative GN ISN/RPS class IV-G (A/C) LN patient showing fibrocellular crescent, MT \times 400	99
Fig. (24)	A glomerulus from diffuse proliferative and sclerosing LN ISN/RPS class IV-S (A/C) showing near total sclerosis, H&E \times 400	99
Fig. (25)	ISN/RPS class III A, AI 5, CI 0 showing mild TWEAK expression intensity (1) with 1/3 extent of expression (3), Allred score 4 mainly tubular \times 100.	100
Fig. (26)	A specimen from ISN/RPS class IV-G (A/C), AI 7/24, CI 4/12 showing mild to moderate TWEAK expression intensity (2) with 1/3 extent of expression (3), Allred score 5, cytoplasmic granular stain of PCT $>$ DCT \times 400.	101
Fig. (27)	Different fields of ISN/RPS class IV-S (A/C), AI 7/24, CI 2/12 showing moderate TWEAK expression intensity (2) with 2/3 extent of	102

List of Figures

Fig. No.	Subject	Page
	expression (4), Allred score 6, mainly PCT \times 200.	
Fig. (28)	ISN/RPS class II, AI 1/24, CI 0/12 showing patchy mild TWEAK expression intensity (1) with 10% extent of expression (2), Allred score 3 \times 200	103
Fig. (29)	Different fields of ISN/RPS class IV-G (A/C), AI 12/24, CI 5/12 showing moderate TWEAK expression intensity (2) with 2/3 extent of expression (4), Allred score 6, granular cytoplasmic and membranous \times 200.	104
Fig. (30)	Different fields of ISN/RPS class III (A/C), AI 7/24, CI 3/12 showing moderate TWEAK expression intensity (2) with 2/3 extent of expression (4), Allred score 6, granular cytoplasmic and membranous \times 200 (a) \times 400(b)	105
Fig. (31)	SN/RPS class IV-G (A/C), AI 17/24, CI 4/12 showing moderate TWEAK expression intensity (2) with 1/3 extent of expression (3), Allred score 5, cytoplasmic and membranous tubular with few mesangial cells stained \times 200	106
Fig. (32)	Different fields of ISN/RPS class III (A/C), AI 7/24, CI 3/12 showing mild TWEAK expression intensity (1) with 2/3 extent of expression (4), Allred score 5, minimal focal staining of PCT \times 200 (a) \times 400 (b)	107
Fig. (33)	SN/RPS class IV-G (A/C), AI 18/24, CI 1/12 showing mild to moderate Fn 14 expression intensity (2) with 1/3 extent of expression (3), Allred score 5, mainly PCT \times 200 (a,b) and \times 400 (c)	109
Fig. (34)	A specimen from ISN/RPS class II, AI 3/24, CI 3/12 showing mesangial (a) and tubular (b) Fn14 expression moderate intensity (2) with 1/3 extent of expression (3), Allred score 5 \times 400.	110

List of Figures

Fig. No.	Subject	Page
Fig. (35)	A specimen showing severe Fn14 expression intensity (3) with 2/3 extent of expression (4), Allred score 7, mainly cytoplasmic and tubular epithelial cells $\times 200$	111
Fig. (36)	A specimen from control with dense inflamed renal core showing moderate Fn14 expression intensity (2) with 10% extent of expression (2), Allred score 4 $\times 200$	112
Fig. (37)	Another specimen showing mild Fn14 expression intensity (1) with 1/3 extent of expression (3), Allred score 4 $\times 100$	112
Fig. (38)	Correlation between urinary TWEAK and C3	116
Fig. (39)	Correlation between urinary TWEAK and C4.	116
Fig. (40)	Correlation between urinary TWEAK and proteinuria.	117
Fig. (41)	Correlation between urinary TWEAK and Activity Index	117
Fig. (42)	ROC curve analysis showing the diagnostic performance of serum TWEAK	120
Fig. (43)	ROC curve analysis showing the diagnostic performance of urinary TWEAK	121